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Abstract
Leishmania protozoan parasites (Trypanosomatidae family) are the causative agents of cu-
taneous, mucocutaneous and visceral leishmaniasis worldwide. While these diseases are
associated with significant morbidity and mortality, there are few adequate treatments avail-
able. Sterol 14alpha-demethylase (CYP51) in the parasite sterol biosynthesis pathway has
been the focus of considerable interest as a novel drug target in Leishmania. However, its
essentiality in Leishmania donovani has yet to be determined. Here, we use a dual biologi-
cal and pharmacological approach to demonstrate that CYP51 is indispensable in L. dono-
vani. We show via a facilitated knockout approach that chromosomal CYP51 genes can
only be knocked out in the presence of episomal complementation and that this episome
cannot be lost from the parasite even under negative selection. In addition, we treated wild-
type L. donovani and CYP51-deficient strains with 4-aminopyridyl-based inhibitors de-
signed specifically for Trypanosoma cruzi CYP51. While potency was lower than in T. cruzi,
these inhibitors had increased efficacy in parasites lacking a CYP51 allele compared to
complemented parasites, indicating inhibition of parasite growth via a CYP51-specific
mechanism and confirming essentiality of CYP51 in L. donovani. Overall, these results pro-
vide support for further development of CYP51 inhibitors for the treatment of
visceral leishmaniasis.
Author Summary
Visceral leishmaniasis is the second most lethal parasitic infection after malaria. Other
forms of leishmaniasis also cause significant morbidity. However, there are few treatments
available, and many cause severe side effects or are associated with the development of
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resistance. A key difference between mammalian cells and Leishmania parasites is the type
of sterol in their membranes: while mammalian cell membranes contain cholesterol, Leish-
mania parasites use ergosterol. There has therefore been considerable interest in develop-
ing inhibitors of sterol biosynthesis pathways to target Leishmania parasites. Sterol
14alpha-demethylase (CYP51) is one of the enzymes in the sterol biosynthesis pathway,
and the target of significant drug development research in Leishmania. Here we use a dou-
ble approach to determine whether this gene is essential in Leishmania donovani, the caus-
ative agent of visceral leishmaniasis. We demonstrate via gene knockout and drug
targeting approaches that loss or inhibition of CYP51 inhibits L. donovani growth. These
results validate CYP51 as a drug target in L. donovani and support further work to develop
CYP51-directed therapies for visceral leishmaniasis.
Introduction
Leishmania are vector-borne protozoan parasites. They have a digenetic lifecycle; promasti-
gotes are transmitted by the sandfly vector to the mammalian host, where they are taken up by
phagocytic cells and differentiate into the amastigote stage within the macrophage phagolyso-
sosme. Amastigotes proliferate within the phagolysosome and can be taken up by a sandfly
during a subsequent bloodmeal. Within the sandfly gut, amastigotes then differentiate into
promastigotes, thereby completing the parasite lifecycle [1].
Leishmania parasites cause a range of disease manifestations: cutaneous leishmaniasis in
which lesions develop at the site of the sandfly bite, mucocutaneous leishmaniasis with destruc-
tion of the mucosal tissues in the nose, mouth and throat, and visceral leishmaniasis in which
parasites disseminate to the liver, bone marrow and spleen. Visceral leishmaniasis is the most
lethal form of the disease. It is associated with high fever, hepatosplenomegaly and pancytope-
nia [1]. The infecting species of Leishmania is the major determinant of disease manifestation;
parasites from the Leishmania donovani species complex are the main causes of visceral leish-
maniasis, while other species, including the Leishmania major species complex, cause cutane-
ous manifestations [2,3].
Leishmania parasites are distributed across tropical and subtropical regions of the world.
350 million people live in endemic areas and are at risk of developing the disease, with 12 mil-
lion people currently infected [4]. Overall, there are 1.6 million new cases per year [5], associat-
ed with a disease burden of 3.3 million DALYs and over 50,000 deaths per year [6], making
leishmaniasis the second most lethal parasitic infection after malaria [5]. However, treatment
options are limited; while recent progress has been made with the development of single-dose
amphotericin B therapy in India [7], this treatment regimen was not effective in East Africa
[8]. All other drugs require long treatment regimens; toxicity and drug resistance are also sig-
nificant concerns [9].
Cell membrane sterols regulate membrane fluidity and contribute to the organization of
membrane domains. Unlike mammalian cells, but similar to fungi, Leishmania and Trypano-
soma parasite cell membranes contain ergosterol and ergosterol-like sterols rather than choles-
terol. Sterols are generated from acetyl-CoA via a multistep metabolic pathway. The first three
steps, catalyzed by acetoacetyl-CoA thiolase, HMG-CoA synthase and HMG-CoA reductase,
lead to the generation of mevalonate. Mevalonate is the substrate of the isoprenoid pathway
that generates farnesyl diphosphate. Squalene synthase then produces squalene from two farne-
syl diphosphate molecules. Squalene is oxidized by squalene oxidase, and the resulting product
cyclized to lanosterol. Sterol 14alpha-demethylase (CYP51, LdBPK_111100.1) catalyses the
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removal of a 14alpha-methyl group from lanosterol [10,11]. The L. infantum CYP51 enzyme
has broad substrate specificity, with the ability to demethylate obtusifoliol, C4-norlanosterol
and 14α-methylzymosterol, in addition to lanosterol, although with a preference for the first
two substrates [12]. The following steps differ between ergosterol and cholesterol biosynthesis,
with variations in the reaction intermediates and enzymes involved depending on species [13].
One of these key latter steps in ergosterol biosynthesis is the methylation of C24 via sterol
24-methyltransferase, leading to the formation of fecosterol, episterol or 5-dehydroepisterol
depending on the substrate [14].
Azole antifungals have been investigated for treatment of Leishmania infections, but with
large variations in efficacy between species [15]. The first experiments on azole sensitivity in
visceral Leishmania species showed efficacy of ketoconazole [16] and oxiconazole [17] on in-
tracellular amastigotes and of ketoconazole on extracellular promastigotes [18]. Posaconazole
[19] and ketoconazole [20] were also effective in mouse models of visceral leishmaniasis, albeit
less so than amphotericin B or pentavalent antimonial compounds currently used for visceral
leishmaniasis treatments. Azoles have also been extensively tested on cutaneous Leishmania
species (see for instance [21,22,23,24] for early work on these parasites). Given the importance
of CYP51 as a drug target and the severity of disease caused by L. donovani, we investigated the
essentiality of L. donovani CYP51 by biological and pharmacological methods.
Materials and Methods
Ethics statement
All vertebrate animal studies were performed in accordance with the USDA Animal Welfare
Act and the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the University of California San Francisco Institutional
Animal Care and Use Committee (protocol AN087316). Euthanasia was performed by carbon
dioxide inhalation followed by cervical dislocation.
Cell culture and infection
L. donovani 1S/Cl2D promastigotes were maintained at 26°C in M199 medium (Sigma) sup-
plemented with 10% heat inactivated fetal bovine serum (FBS, Sigma), 25 mMHEPES, penicil-
lin, streptomycin, adenosine, glutamine, hemin, and folic acid at pH 7.2. Axenic amastigote
differentiation was performed as described in [25]: promastigotes were resuspended in amasti-
gote media (M199 medium supplemented with 25% FBS, streptomycin, penicillin, succinic
acid, adenine, glycerol, L-proline and folic acid, at pH 5.5) at a cell density of 5x106 cells/mL
and transferred to 37°C, 5% CO2.
THP-1 macrophages were maintained in RMPI 1640 media supplemented with 5% FBS 1%
penicillin-streptomycin at 37°C, 5% CO2. For Leishmania infection, THP-1 cells were treated
with 50 ng/mL phorbol 12-myristate 13-acetate (PMA) for 48 h and then infected with station-
ary phase promastigotes. Cells were then fixed with 4% formaldehyde and stained with
40,60-diamidino-2-phenylindole (DAPI). Images were obtained with an automated InCell 2000
automated imaging system (G.E. Healthcare) and parasite levels determined using IN CELL
developer 1.9 software (see S1 Methods), leading to determination of cell boundaries and
counting of parasite inside the boundary but outside the nucleus in an automated fashion.
Female BALB/c mice (17–20 g, 6 per group) were purchased from Simonsen Laboratories
and maintained in the animal care facility under pathogen-free conditions. Mice were infected
intravenously via the tail vein with 5x107 stationary phase promastigotes and sacrificed 28 days
post- infection. Liver parasite burden was determined by direct counting of amastigotes on
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Diff-Quick stained liver impressions and calculated as Leishman-Donovan Units (LDU): num-
ber of amastigotes per 1000 cell nuclei × liver weight (g).
Generation of transfected L. donovani lines
All sequences were retrieved from TriTrypDB [26]. 30 L. donovani CYP51 flanking sequences
was amplified by PCR from parasite genomic DNA (LdBPK_111100.1, primers 1 and 2),
digested with SpeI and XbaI, and ligated into the XbaI site of vectors pGEM-PAC and pGEM-
Hyg. 50 CYP51 flanking region was amplified with primers 3 and 4, digested with SpeI XbaI,
and ligated into the SpeI site of vectors already containing the CYP51 30 flanking region.
Knockout cassettes were then liberated by restriction enzyme digestion with SpeI XbaI. The
CYP51 coding region was amplified by PCR from genomic DNA (primers 5 and 6), digested
with BglII and ligated into the BglII site of the pXNG4 vector [27]. In all cases, constructs were
verified by diagnostic digest and sequencing.
Transfection was performed as described in [28] by electroporation in cytomix transfection
buffer (120mM KCl, 0,15mM CaCl2, 10mM K2HPO4, 25mMHEPES, 2mM EDTA, 2mM
MgCl2) using a BioRad Gene Pulser Xcell, delivering two pulses at 1500 V and 25 μF. Parasites
were transfected first with the hygromycin knockout cassette; HKO clonal lines were selected
with 100 μg/ml hygromycin (Invitrogen), then transfected with the empty pXNG4 vector or
the pXNG4 vector encoding CYP51, thereby generating the HKO + C and HKO + CYP lines,
respectively. Double transfectants were maintained with a combination of hygromycin and 100
μg/ml nourseothricin (GoldBio). HKO + C or HKO + CYP lines were transfected with the pu-
romycin knockout cassette and clonal HKO + C + PAC and HKO + CYP + PAC lines isolated
by limiting dilution under selection with hygromycin, nourseothricin and 20 μg/ml puromycin
(Sigma). Correct targeting of CYP51 genes was verified by PCR using primers 7 (in CYP51
50UTR) and 8 (in hygromycin resistance gene) or 9 (in puromycin resistance gene). Persistence
of CYP51 genes in double resistant, uncomplemented strains and loss of chromosomal CYP51
in complemented strains were verified by PCR (primers 10 + 11 and primers 12 + 13, respec-
tively). Primer 12 is upstream of CYP51, outside of the knockout cassette, and primer 13 an-
neals within the CYP51 gene.
Ganciclovir selection
50 μg/mL ganciclovir (Invivogen) was added to the parasite cultures. qPCR on extracted DNA
to monitor pXNG4 loss and flow cytometry analysis to assess GFP levels were performed week-
ly (see below). Results shown represent the average of two independent selection experiments
on a total of seven independent clonal lines.
Quantitative PCR
DNA was extracted as described previously [29]. qPCR reactions containing 100 ng of parasite
DNA in Lightcycler 480 Sybr green I Master mix (Roche) were run on a Stratagene Mx3005P
RT-PCR thermocycler using the following thermal profile: initial denaturation at 95°C for
10 min, then 40 cycles of denaturation at 95°C for 10 s, annealing at 57°C for 20 s and extension
at 72°C for 20 s. Melting curve analysis and agarose gel electrophoresis were used to confirm
correct PCR product formation. Chromosomal CYP51 (primers 14 and 15), total CYP51 (prim-
ers 16 and 17), and pXNG4 (primers 18 and 19) relative levels were determined by qPCR using
the 2-ΔΔCt method [30], normalizing to serine acetyltransferase (SAT, primers 20 and 21) or
cystathionine beta-synthase (CBS, primers 22 and 23), previously shown to be present in only
two copies in L. donovani [31].
Essentiality of Leishmania donovani CYP51
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588 March 13, 2015 4 / 17
Flow cytometry
Analyses were performed on a BDFACSDiva LSRII flow cytometer in HTS mode. Cells were
stained with 5 μM propidium iodide (PI, Sigma). Quadrant gates were set used PI-stained
wild-type parasites (GFP-negative) and percentage of GFP+ PI- cells determined using FloJo X
software (Tree Star Inc).
SDS PAGE andWestern blot
1x107 parasites were lysed in 1x LDS buffer (Invitrogen) and separated using NuPage bis-tris
precast polyacrylamide gels (Invitrogen). Proteins were transferred to a PVDF membrane
(BioRad). Western blot was performed as described in [32]. Affinity-purified anti-CYP51 anti-
bodies (Genescript) and anti-GAPDH antibody (from Paul Michels, Université catholique de
Louvain, Bruxelles) were used at 1:5,000 dilution. The secondary antibody was a 1:5,000 dilu-
tion of peroxidase-conjugated anti-rabbit IgG antibody (GE Healthcare). All proteins were vi-
sualized using SuperSignal West Pico Chemoluminescent Substrate (Thermo Scientific).
Proteins expression levels were quantified with Image J program, normalizing CYP51 levels to
GAPDH levels.
Sterol GC-MS
Sterol extraction was performed as described in [33]. Briefly, the parasite cell pellet was resus-
pended in chloroform-methanol solution (2:1 ratio), then dried under nitrogen gas, followed
by overnight treatment with chloroform. The organic phase was then washed with water and
dried under nitrogen. The dried pellet was resuspended in chloroform-methanol (9:1 ratio),
and washed again with water. Acetonitrile was added to the samples, washing steps were re-
peated and solvents evaporated under nitrogen.
Extracted sterols were then derivatized by resuspending the dried residue in 25 μL hexanes
and 75 μL BSTFA (Sigma-Aldrich, St. Louis MO) for 2 hr at 37°C to generate the trimethylsilyl
(TMS) sterols. TMS-derivatized sterols were analyzed using gas chromatography-mass spec-
trometry (GC-MS) on an Agilent HP 6850 GC coupled to a mass selective detector (Agilent
MSD 5973) operating at 70 eV in electron impact mode. The sterols were separated using a
DB5-MS analytical column (30 m x 0.25 mm inner diameter, 0.25-μm film thickness, Agilent)
with a temperature profile that begins at 200°C for 1 min, increases by 15°C/min up to 300°C,
and holds at 300°C for 20 min. The inlet and detector temperatures were held at 200 and
250°C, respectively. The MSD was set to scan the range 50–750m/z for sterol profiling. Selected
Ion Monitoring (SIM) was used for ergosterol quantification by using the same GC tempera-
ture profile but assaying for fragment ions specific to ergosterol that elute at the same time win-
dow as ergosterol standard:m/z 468.4, 378.4, 363.4, 337.4, and 253.1 We prepared an 8-point
standard curve of ergosterol using serial dilution over a concentration range of 9 pmol to 1.2
nmoles. The area under the curve in the SIM assay was then compared to standard samples to
calculate ergosterol concentrations.
Ergosterol biosynthesis inhibitor assay
Amphotericin B, ketoconazole and voriconazole were purchased from Sigma. All other CYP51
inhibitors were synthesized in-house (see supplementary methods and [34,35,36]). Stationary
phase promastigotes (8x105/mL) were treated for 72 h with two-fold dilution of inhibitors in
384 well plate format. Resazurin (0.025 mg/mL, Santa Cruz) was added for 5 h, cells were fixed,
and fluorescence measured at 490 nm excitation and 595 nm emission wavelengths. Data was
normalized to the amphotericin B positive control and DMSO vehicle negative control for each
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plate, and EC50 values calculated using Collaborative Drug Discovery Vault software. T. cruzi
cell-based activity was determined by high content screening in triplicate, as previously de-
scribed [36].
Results
Leishmania donovani tolerate modulations in CYP51 levels
We generated half knockout L. donovani parasites (HKO strains) in which a single CYP51 allele
was replaced with either a puromycin or hygromycin resistance marker (Fig. 1A; see Fig. 2B for
the knockout approach). CYP51 is located on chromosome 11, which is disomic in reference
L. donovani genomes [37], but trisomic in some clinical L. donovani isolates [31]. In addition,
the Leishmania genome contains many direct and indirect repeats that can promote extrachro-
mosomal element formation under drug pressure or for essential genes [31,38]. Prior to target-
ing another CYP51 allele, we therefore verified CYP51 copy number in parasites transfected
with the first knockout cassette, resistant to either hygromycin (HygR HKO strains) or puro-
mycin (PAC HKO strains). HKO strains contained half of the CYP51 DNA content found in
wild-type, indicating loss of one out of two alleles (Fig. 1B). Furthermore, CYP51 protein levels
were decreased two to five fold in half knockout strains. Complementation with an episomal
CYP51 gene restored protein expression to levels comparable to wild-type L. donovani
(Fig. 1C).
Given the importance of ergosterol biosynthesis in trypanosomatid parasites, we assessed
the impact of this loss of CYP51 expression before proceeding to targeting of the second
CYP51 allele. In vivo and in vitro infectivity was comparable between strains (Fig. 1D, Fig. 1E,
S1 Fig); any differences between wild-type and transfected strains were not due to changes in
CYP51 levels since infectivity of HKO, HKO+C and HKO+CYP was comparable. These strains
also all had comparable sterol profiles (Fig. 1F) and ergosterol levels (Table 1).
Essentiality of CYP51: Biological approach
Since L. donovani parasites were able to tolerate over two-fold reductions in CYP51 protein lev-
els with no apparent effects on parasite phenotype, we then proceeded to targeting the second
CYP51 allele. However, while we obtained correct targeting of CYP51 with hygromycin and pu-
romycin resistance markers, double drug-resistant parasites still retained CYP51, despite multi-
ple targeting attempts (Fig. 2A). We therefore used a facilitated knockout approach (Fig. 2B)
[27,39,40], targeting the second CYP51 allele in the presence of episomal CYP51 complementa-
tion. As a control, we targeted this second allele in parasites transfected with the empty pXNG4
vector [27] (S2 Fig.). We obtained complete loss of chromosomal CYP51 genes only in the pres-
ence of episomal CYP51; genomic CYP51 was retained in the parasites transfected with the
empty plasmid, supporting essentiality of CYP51 (Fig. 2C).
The pXNG4 vector used for complementation also encodes a green fluorescence protein
gene (GFP) and a herpes virus thymidine kinase gene; cells that contain the plasmid are sensi-
tive to treatment with ganciclovir (GCV). We therefore performed negative selection against
the pXNG4 vector by treating transfected parasites with GCV. Plasmid persistence during
GCV treatment was monitored by qPCR and by flow cytometry for GFP. The pXNG4 plasmid
was lost much faster from parasites transfected with the empty vector (retain chromosomal
CYP51) than from parasites transfected with the vector encoding CYP51 (only source of
CYP51), indicating selection for CYP51 persistence (Fig. 2D, 2E). One clonal line (HKO1 +
CYP + PAC2) showed greater loss of pXNG4 plasmid, but still retained CYP51 DNA levels
comparable to half knockout strains, with 2^(-ΔΔCt) values of 0.6, leading to ergosterol levels
Essentiality of Leishmania donovani CYP51
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Fig 1. Modulation of CYP51 levels in L. donovani. A, Replacement of a CYP51 allele by homologous recombination. Correct targeting of the knockout
cassettes was verified by PCR using one primer within the knockout cassette and one upstream of CYP51 (primers 7 and 8 (hygromycin), top or 7 and 9
(puromycin), bottom). B, qPCR quantification of chromosomal CYP51 levels, normalized to SAT or to CBS and to wild-type levels. C, CYP51 protein levels in
half knockout and complemented strains. CYP51 and GAPDHwere detected byWestern blot (top) and quantified by densitometry (bottom)D, In vitro
infectivity of half knockout and complemented strains. THP1macrophages were infected at a 10:1 parasite to macrophage ratio. Cells were fixed and stained
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similar to wild-type, even after 7 weeks of GCV selection (S4 Fig). Overall, these results support
essentiality of CYP51 in L. donovani.
Essentiality of CYP51: Pharmacological approach
The persistence of CYP51-encoding pXNG4 plasmids even under GCV negative selection indi-
cates that CYP51 is essential in L. donovani. Pharmacological inhibition of CYP51 should
therefore lead to parasite growth arrest and death. The 4-aminopyridyl-based compound series
of CYP51 inhibitors was derived from an initial hit in target-based high-throughput screening,
followed by hit-to-lead optimization using structure-activity relationships (SAR), structure-
property relationships (SPR), and biological and structural evaluation for T. cruzi CYP51
[34,35,36,41,42,43,44]. We tested 205 compounds from this series on wild-type intracellular L.
donovani amastigotes by high content assay. Fifty-four compounds with over 60% activity at
10 μMwere then used for dose-response experiments on wild-type L. donovani promastigotes
and strains in which we modulated CYP51 expression (HKO, HKO+C and HKO+CYP). Rep-
resentative compounds with the highest activity on promastigotes are shown in Fig. 3, Fig. 4.
Activity on intracellular amastigotes is shown in S3 Table. No clear difference in EC50 values
were observed between strains with ketoconazole and voriconazole controls, possibly due to
their lower activity on L. donovani. In-house compounds were more potent in this assay than
the commercial antifungal azoles. Overall, HKO+CYP strains were less sensitive to these 4-
aminopyridyl-based inhibitors compared to HKO+C, indicating that these compounds inhibit
Leishmania growth via a CYP51-mediated mechanism. This confirms that targeting CYP51
pharmacologically promotes inhibition of parasite growth, further supporting essentiality of
CYP51 in L. donovanimetabolism.
Discussion
CYP51 (sterol 14alpha-demethylase) belongs to the large cytochrome P450 enzyme family,
which contains over 20,000 members. While there is significant variation at the sequence level,
CYP51 is highly conserved across eukaroytes at the structural level [45]. However, small varia-
tions between species and strains can lead to significant variations in sensitivity to CYP51 in-
hibitors. Indeed, a single amino acid change in CYP51 in T. cruzi Y strain compared to
Tulahuen strain was associated with significant decrease in sensitivity to two CYP51 inhibitors,
at concentrations that caused 100% inhibition of the Tulahuen enzyme [46].
In vitro side-by-side comparison of azole efficacy on promastigotes between Leishmania
species provides conflicting results: two studies observed increased susceptibility of six different
L. donovani strains to ketoconazole and itraconazole compared to six different L.major strains
[14,18], while other studies on different L. donovani and L.major strains indicated that L.
donovani is more resistant to ketoconazole [47] and posaconazole [19] than L.major. In a sepa-
rate study, intracellular L. donovani amastigotes were more sensitive to ketoconazole than
amastigotes from cutaneous leishmaniasis patients [16]. L.major promastigotes were also in-
sensitive to our 4-aminopyridyl-based compound series of CYP51 inhibitors, even with a lon-
ger exposure to the compounds (S2 Table). With regards to clinical trials, azoles have shown
large variations in clinical efficacy between Leishmania species, from no effect to almost 90%
efficacy [15], although the majority of these studies have focused on cutaneous leishmaniasis.
While there is a single case report of successful posaconazole use to treat cutaneous
with DAPI 24, 48 and 72 h post-infection, and macrophage infection levels were determined by automated high-throughput imaging and parasite detection. E,
In vivo infectivity of half knockout and complemented strains. BALB/c mice were infected intravenously. Liver parasite burden (Leishman-Donovan Units,
LDU) was determined 28 days post-infection by counting stained liver impressions. F, Sterol profiling by GC-MS.
doi:10.1371/journal.pntd.0003588.g001
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Fig 2. Essentiality of CYP51 in L. donovani. A, Persistence ofCYP51 gene even after correct targeting of two knockout cassettes into theCYP51 locus.
Correct targeting of the knockout cassettes was verified by PCR using one primer within the knockout cassette and one upstream of CYP51 (primers 7 and 8
(hygromycin) or 7 and 9 (puromycin)). CYP51was amplified with primers within the coding region (primers 10 and 11). B, Targeting strategy. Primers 7 and 8
or 7 and 9 and expected PCR product sizes to confirm correct targeting of chromosomal CYP51 alleles are indicated by arrows (step 4). C, Loss of
chromosomal CYP51 in the presence of episomalCYP51 complementation but not in strains complemented with the empty vector. PCR was performed
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leishmaniasis caused by L. donovani infantum [48], to our knowledge there has been no clinical
trial of azoles for visceral leishmaniasis. Persistent Leishmania growth in the presence of azoles
has been tied to tolerance to 14-methyl sterol accumulation in parasite membranes [14,18,49]
as well as increased exogenous cholesterol incorporation [18].
Recent work indicated that CYP51 appears to be dispensable in L.major, albeit at a high fit-
ness cost [14]. In contrast, given (1) our inability to fully knockout chromosomal CYP51 unless
we provide an extrachromosomal episomal source of CYP51, (2) the persistence of this CYP51
episome during negative selection under conditions in which it is the only source of CYP51,
and (3) the CYP51-specific growth inhibition of 4-aminopyridyl-based non-azole CYP51 in-
hibitors in L. donovani, our results support essentiality of CYP51 in L. donovani. While extra-
chromosomal episomal-encoded CYP51 could not fully complement the knockout phenotype,
it was indeed active, given its ability to substitute for chromosomal CYP51 and to increase re-
sistance to the 4-aminopyridyl-based non-azole CYP51 inhibitors which directly target the
CYP51 active site [13,34,36].
L. donovani and L.major CYP51 are overall very similar. Comparing the L.major and L.
donovani CYP51 protein sequences highlights two amino acid substitutions in β helices 1–1
and 1–2 and a single amino acid insertion at the C-terminal in L. donovani compared to
L.major (S5 Fig). This suggests that other mechanisms may be responsible for the observed dif-
ferences in CYP51 essentiality between L.major and L. donovani. Indeed, squalene synthase,
which catalyzes the first committed step in ergosterol biosynthesis, has been involved in resis-
tance to itraconazole [50]; differences in sensitivity to some squalene synthase inhibitors were
observed between L.major and L. donovani [51]. Likewise, there were differences in sensitivity
to sterol 24-methyltransferase inhibitors between L.major and L. donovani [52]. Finally, the
activity of L. donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reduc-
tase) was 50-fold higher than the activity of the L.major enzyme [53]. HMG-CoA reductase
using primers 12+13.D, pXNG4 loss monitored by qPCR during GCV selection or in the absence of either positive or negative selection (untreated samples).
pXNG4 Ct values were normalized to SAT levels and to samples under positive selection (treated with nourseothricn (NTC) in the absence of GCV). E, GFP
positive, propidium iodide (PI) negative levels were monitored by flow cytometry. Percentage of GFP+ PI- cells were normalized to the levels for week 1. *,
p<0.05 compared to HKO+CYP+PAC.
doi:10.1371/journal.pntd.0003588.g002
Table 1. Ergosterol levels in half knockout strains.
Stage Strain Ergosterol levels (pmol)a
Promastigotes Wild-type 7236.7
HKO 5167.3
HKO + C 7535.2
HKO + CYP 5887.9
Axenic amastigotes Wild-type 1374.7
HKO 1102.8
HKO + C 904.4
HKO + CYP 983.3
Intracellular amastigotes Wild-type 135.2
HKO 165.3
HKO + C 462.0
HKO + CYP 327.7
a Normalized to host cholesterol levels for intracellular amastigotes
doi:10.1371/journal.pntd.0003588.t001
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catalyzes the third step of sterol synthesis from acetyl-CoA and is the rate-limiting step in
human sterol biosynthesis [54]. Finally, another member of the cytochrome P450 family,
CYP5122A1 (LdBPK_270090.1), also modulates ergosterol levels in L. donovani [55]; its ex-
pression or activity could be altered in CYP51-deficient L.major, to complement for loss of
CYP51.
Beyond differences in CYP51 and sterol biosynthetic pathways between L.major and
L. donovani, additional factors could also contribute to this observed difference in CYP51
Fig 3. Susceptibility of half knockout strains to CYP51 inhibitors (EC50, μM): compounds with no significant differences between HKO + C and
HKO + CYP strains. Values ± standard error are shown. a p-values are for comparison between HKO+C and HKO+CYP.
doi:10.1371/journal.pntd.0003588.g003
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essentiality. Indeed, Xu et al showed that L.major CYP51 is involved in protection against heat
shock [14]. L.major is considerably more sensitive to heat shock than L. donovani, but the
mechanism of resistance to heat shock differs between these species, with the L. donovani-spe-
cific A2 protein family a key contributor to L. donovani survival during heat stress [25,32].
Likewise, gp63 and lipophosphoglycan levels were altered in CYP51-deficient L.major [14].
Lipophosphoglycan is structurally different between L.major and L. donovani [56], and gp63
from members of the L. donovani species complex is less active than L.major gp63 [57].
Fig 4. Susceptibility of half knockout strains to CYP51 inhibitors (EC50, μM): compounds with decreased activity on HKO + CYP strains. Values ±
standard error are shown. a p-values are for comparison between HKO+C and HKO+CYP.
doi:10.1371/journal.pntd.0003588.g004
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Overall, our results support further investigation of CYP51 inhibitors for the treatment of vis-
ceral leishmaniasis. While recent clinical trial results using posaconazole for the treatment of
Chagas disease were disappointing [58], the enhanced potency we observed in L. donovani for 4-
aminopyridyl-based non-azole inhibitors of CYP51 compared to ketoconazole and voriconazole
supports the development of novel inhibitor scaffolds, potentially using our 4-aminopyridyl in-
hibitor series as a starting point. Given the lower efficacy of these inhibitors on Leishmania com-
pared to T. cruzi, efforts should be made through further medicinal chemistry to optimize both
pharmacodynamic and pharmacokimetic properties of these compounds for activity against
Leishmania. In particular, efficacy was much lower for intracellular wild-type L. donovani amas-
tigotes compared to our transfected promastigote strains (S3 Table), possibly due to additional
constraints with regards to drug uptake into the host cell and into the parasite-containing acidic
phagolysosome. Finally, this work and the work of others indicate that CYP51-targeted therapies
may not be suitable to treat all Leishmania species. This highlights the importance of considering
variations between species and strains early during the drug development process.
Supporting Information
S1 Methods. Supplemental methods.
(DOC)
S1 Scheme. Synthesis of CYP51 inhibitors. Reagents and conditions: (a) Arylboronic acid,
5 mol% Pd2(dba)3, 10 mol% PCy3, 2M K3PO4, dioxane, 100°C (microwave), 1h, ca. 90% (b)
1-(aryl)piperazine, Pd(OAc)2, P(o-tolyl)3, Cs2CO3, toluene, 50°C, 48 h, ca. 70% (c) 10% NaOH
(aq), MeOH/THF (1/1), 60°C, 3 h, ca. 95% (d) 11, 12, 13, 14, 15, 16, 17, 18b, 19b, and 20b (as
appropriate), PyBOP, HOBt, Et3N, CH2Cl2, 23°C, 1h, ca. 50%.
(PPT)
S1 Fig. In vitro infectivity of half knockout and complemented strains. THP1 macrophages
were infected at a 10:1 parasite to macrophage ratio. Cells were fixed and stained with DAPI
24, 48 and 72 h post-infection, and parasite numbers per infected cell were determined by auto-
mated high-throughput imaging and parasite detection
(PPT)
S2 Fig. Targeting of hygromycin and puromycin resistance knockout cassettes. Correct tar-
geting of the hygromycin (A) and puromycin (B) resistance knockout cassettes was verified by
PCR using one primer upstream of CYP51 and one specific to the resistance marker (primers 7
and 8 (hygromycin) or 7 and 9 (puromycin)). HKO1 + CYP + PAC clones 2, 4, 5; HKO2 + C +
PAC clones 1, 2 and 3; HKO2 + CYP + PAC clones 1, 2, 4 and 5 have correct targeting of both
knockout cassettes.
(PPT)
S3 Fig. Representative flow cytometry analysis at five weeks of GCV selection. Parasites
were treated with NTC (positive selection), GCV (negative selection) or left untreated (-NTC-
GCV) for five weeks. One representative cell line is shown for HKO + C + PAC and for HKO +
CYP + PAC. A, Quadrant analysis. Numbers indicate the percentage of cells in each quadrant.
B, Representative GFP histogram plots of PI-negative cells. Wild-type parasites (dotted line)
serve as the non-fluorescent cutoff reference. Black, NTC treatment (positive selection). Grey,
GCV treatment (negative selection).
(PPT)
S4 Fig. Persistence of CYP51 in HKO1 + CYP + PAC2 strain. CYP51 persistence was as-
sessed by qPCR (A) and Western blot (B) following seven weeks of GCV selection. Sterol
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profiles and ergosterol levels were determined by GC-MS (C). Chol., cholesterol.
Erg, ergosterol.
(PPT)
S5 Fig. Alignment of L.major and L. donovani CYP51. A, Clustal Omega alignment. β 1–1
and 1–2 helices are positioned as in [12]. B, Secondary structure alignment. 3-D models of L.
major and L. donovani CYP51 were generated using the I-TASSER server. The top scoring
models were overlaid using UCSF Chimera. Red, L. donovani. Blue, L.major.
(PPT)
S1 Table. Oligonucleotides used in this study.
(XLS)
S2 Table. Susceptibility of L.major to CYP51 inhibitors (EC50, μM).
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S3 Table. Susceptibility of intracellular L. donovani amastigotes to select CYP51 inhibitors.
(DOC)
Acknowledgments
We wish to thank Dr Stephen Beverley, Washington University in St. Louis, for providing the
pXNG4 plasmid, Dr Julio Urbina, Venezuelan Institute for Scientific Research (IVIC), for fruit-
ful discussions and suggestions, Dr Claudia Calvet for the anti-CYP51 antibody, Dr Paul
Michels, Université catholique de Louvain, Bruxelles for the anti-GAPDH antibody, and Brian
Suzuki for help with the intravenous infections. The authors also thank the Ortiz de Montel-
lano laboratory at UCSF for use of the GC-MS instrument.
Author Contributions
Conceived and designed the experiments: LIM GDMWRR LMP JHM. Performed the experi-
ments: LIM AEA JYC DFV GDM JBJ DK. Analyzed the data: LIM DFV JBJ SC JLSN. Contrib-
uted reagents/materials/analysis tools: JYCWRR LMP JHM. Wrote the paper: LIM JYC.
References
1. Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366:
1561–1577. PMID: 16257344
2. McCall LI, McKerrow JH (2014) Determinants of disease phenotype in trypanosomatid parasites.
Trends in Parasitology 30: 342–349. doi: 10.1016/j.pt.2014.05.001 PMID: 24946952
3. McCall LI, ZhangWW, Matlashewski G (2013) Determinants for the development of visceral leishmani-
asis disease. PLoS Pathog 9: e1003053. doi: 10.1371/journal.ppat.1003053 PMID: 23300451
4. Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol In-
fect Dis 27: 305–318. PMID: 15225981
5. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis Worldwide and Global Es-
timates of Its Incidence. Plos One 7: e35671. doi: 10.1371/journal.pone.0035671 PMID: 22693548
6. Hotez PJ, Alvarado M, Basanez MG, Bolliger I, Bourne R, et al. (2014) The global burden of disease
study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis 8:
e2865. doi: 10.1371/journal.pntd.0002865 PMID: 25058013
7. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW (2010) Single-Dose Liposomal Amphotericin B
for Visceral Leishmaniasis in India. New England Journal of Medicine 362: 504–512. doi: 10.1056/
NEJMoa0903627 PMID: 20147716
8. Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, et al. (2014) Safety and Efficacy of Single
Dose versus Multiple Doses of AmBisome(R) for Treatment of Visceral Leishmaniasis in Eastern Africa:
A Randomised Trial. PLoS Negl Trop Dis 8: e2613. doi: 10.1371/journal.pntd.0002613 PMID:
24454970
Essentiality of Leishmania donovani CYP51
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588 March 13, 2015 14 / 17
9. Monge-Maillo B, Lopez-Velez R (2013) Therapeutic options for visceral leishmaniasis. Drugs 73:
1863–1888. doi: 10.1007/s40265-013-0133-0 PMID: 24170666
10. Lepesheva GI, Waterman MR (2011) Sterol 14alpha-demethylase (CYP51) as a therapeutic target for
human trypanosomiasis and leishmaniasis. Current topics in medicinal chemistry 11: 2060–2071.
PMID: 21619513
11. de SouzaW, Rodrigues JC (2009) Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid
Drugs. Interdisciplinary perspectives on infectious diseases 2009: 642502. doi: 10.1155/2009/642502
PMID: 19680554
12. Hargrove TY, Wawrzak Z, Liu J, NesWD, Waterman MR, et al. (2011) Substrate preferences and cata-
lytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from
Leishmania infantum. J Biol Chem 286: 26838–26848. doi: 10.1074/jbc.M111.237099 PMID:
21632531
13. Choi JY, Podust LM, RoushWR (2014) Drug Strategies Targeting CYP51 in Neglected Tropical Dis-
eases. Chemical Reviews. E-pub ahead of print.
14. XuW, Hsu F-F, Baykal E, Huang J, Zhang K (2014) Sterol Biosynthesis Is Required for Heat Resis-
tance but Not Extracellular Survival in Leishmania. PLoS Pathog 10: e1004427. doi: 10.1371/journal.
ppat.1004427 PMID: 25340392
15. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis.
The Lancet infectious diseases 7: 581–596. PMID: 17714672
16. Berman JD (1982) In vitro susceptibility of antimony-resistant Leishmania to alternative drugs. The
Journal of infectious diseases 145: 279. PMID: 6274970
17. Gebre-Hiwot A, Frommel D (1993) The in-vitro anti-leishmanial activity of inhibitors of ergosterol biosyn-
thesis. The Journal of antimicrobial chemotherapy 32: 837–842. PMID: 8144423
18. Beach DH, Goad LJ, Holz GG Jr. (1988) Effects of antimycotic azoles on growth and sterol biosynthesis
of Leishmania promastigotes. Molecular and Biochemical Parasitology 31: 149–162. PMID: 2847043
19. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC (1999) Efficacy of the triazole SCH 56592 against
Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral
leishmaniases. Antimicrobial Agents and Chemotherapy 43: 2910–2914. PMID: 10582881
20. Gangneux JP, Dullin M, Sulahian A, Garin YJ, Derouin F (1999) Experimental evaluation of second-line
oral treatments of visceral leishmaniasis caused by Leishmania infantum. Antimicrobial Agents and
Chemotherapy 43: 172–174. PMID: 9869587
21. Hart DT, Lauwers WJ, Willemsens G, Vanden Bossche H, Opperdoes FR (1989) Perturbation of sterol
biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macro-
phages. Molecular and Biochemical Parasitology 33: 123–134. PMID: 2542790
22. Berman JD, Goad LJ, Beach DH, Holz GG (1986) Effects of Ketoconazole on Sterol Biosynthesis by
Leishmania-Mexicana Mexicana Amastigotes in Murine Macrophage Tumor-Cells. Molecular and Bio-
chemical Parasitology 20: 85–92. PMID: 3736597
23. Berman JD, Gallalee JV (1987) In vitro antileishmanial activity of inhibitors of steroid biosynthesis and
combinations of antileishmanial agents. The Journal of parasitology 73: 671–673. PMID: 3037057
24. Goad LJ, Holz GG Jr., Beach DH (1985) Sterols of ketoconazole-inhibited Leishmania mexicana mexi-
cana promastigotes. Molecular and Biochemical Parasitology 15: 257–279. PMID: 4033689
25. McCall LI, Matlashewski G (2012) Involvement of the Leishmania donovani virulence factor A2 in pro-
tection against heat and oxidative stress. Exp Parasitol 132: 109–115. doi: 10.1016/j.exppara.2012.06.
001 PMID: 22691540
26. Aslett M, Aurrecoechea C, Berriman M, Brestelli J, Brunk BP, et al. (2010) TriTrypDB: a functional ge-
nomic resource for the Trypanosomatidae. Nucleic Acids Research 38: D457–D462. doi: 10.1093/nar/
gkp851 PMID: 19843604
27. Murta SM, Vickers TJ, Scott DA, Beverley SM (2009) Methylene tetrahydrofolate dehydrogenase/cyclo-
hydrolase and the synthesis of 10-CHO-THF are essential in Leishmania major. Mol Microbiol 71:
1386–1401. doi: 10.1111/j.1365-2958.2009.06610.x PMID: 19183277
28. Robinson KA, Beverley SM (2003) Improvements in transfection efficiency and tests of RNA interfer-
ence (RNAi) approaches in the protozoan parasite Leishmania. Molecular and Biochemical Parasitolo-
gy 128: 217–228. PMID: 12742588
29. Medinaacosta E, Cross GAM (1993) Rapid Isolation of DNA from Trypanosomatid Protozoa Using a
Simple Mini-Prep Procedure. Molecular and Biochemical Parasitology 59: 327–329. PMID: 8341329
30. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative
PCR and the 2(T)(-Delta Delta C) method. Methods 25: 402–408. PMID: 11846609
Essentiality of Leishmania donovani CYP51
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588 March 13, 2015 15 / 17
31. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, et al. (2011) Whole genome sequencing
of multiple Leishmania donovani clinical isolates provides insights into population structure and mecha-
nisms of drug resistance. Genome Research 21: 2143–2156. doi: 10.1101/gr.123430.111 PMID:
22038251
32. McCall LI, Matlashewski G (2010) Localization and induction of the A2 virulence factor in Leishmania:
evidence that A2 is a stress response protein. Mol Microbiol 77: 518–530. doi: 10.1111/j.1365-2958.
2010.07229.x PMID: 20497497
33. Gunatilleke SS, Calvet CM, Johnston JB, Chen CK, Erenburg G, et al. (2012) Diverse inhibitor chemo-
types targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis 6: e1736. doi: 10.1371/journal.pntd.
0001736 PMID: 22860142
34. Choi JY, Calvet CM, Vieira DF, Gunatilleke SS, Cameron MD, et al. (2014) R-Configuration of 4-Amino-
pyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi. Acs Medici-
nal Chemistry Letters 5: 434–439. doi: 10.1021/ml500010m PMID: 24900854
35. Choi JY, Calvet CM, Gunatilleke SS, Ruiz C, Cameron MD, et al. (2013) Rational development of 4-
aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents. Journal of
Medicinal Chemistry 56: 7651–7668. doi: 10.1021/jm401067s PMID: 24079662
36. Calvet CM, Vieira DF, Choi JY, Kellar D, Cameron MD, et al. (2014) 4-Aminopyridyl-based CYP51 in-
hibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo poten-
cy. Journal of Medicinal Chemistry 57: 6989–7005. doi: 10.1021/jm500448u PMID: 25101801
37. Rogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates PA, et al. (2011) Chromosome and gene copy num-
ber variation allow major structural change between species and strains of Leishmania. Genome Re-
search 21: 2129–2142. doi: 10.1101/gr.122945.111 PMID: 22038252
38. Ubeda JM, Raymond F, Mukherjee A, Plourde M, Gingras H, et al. (2014) Genome-wide stochastic
adaptive DNA amplification at direct and inverted DNA repeats in the parasite leishmania. PLoS biology
12: e1001868. doi: 10.1371/journal.pbio.1001868 PMID: 24844805
39. Dacher M, Morales MA, Pescher P, Leclercq O, Rachidi N, et al. (2014) Probing druggability and biolog-
ical function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle
analyses. Mol Microbiol.
40. Norris-Mullins B, VanderKolk K, Vacchina P, Joyce MV, Morales MA (2014) LmaPA2G4, a Homolog of
Human Ebp1, Is an Essential Gene and Inhibits Cell Proliferation in L. major. PLoS Negl Trop Dis 8:
e2646. doi: 10.1371/journal.pntd.0002646 PMID: 24421916
41. Podust LM, von Kries JP, Eddine AN, Kim Y, Yermalitskaya LV, et al. (2007) Small-molecule scaffolds
for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. Anti-
microbial Agents and Chemotherapy 51: 3915–3923. PMID: 17846131
42. Vieira DF, Choi JY, RoushWR, Podust LM (2014) Expanding the binding envelope of CYP51 inhibitors
targeting Trypanosoma cruzi with 4-Aminopyridyl-based sulfonamide derivatives. Chembiochem: a Eu-
ropean journal of chemical biology 15: 1111–1120. doi: 10.1002/cbic.201402027 PMID: 24771705
43. Chen CK, Doyle PS, Yermalitskaya LV, Mackey ZB, Ang KK, et al. (2009) Trypanosoma cruzi CYP51
inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl Trop Dis 3: e372. doi: 10.
1371/journal.pntd.0000372 PMID: 19190730
44. Doyle PS, Chen CK, Johnston JB, Hopkins SD, Leung SS, et al. (2010) A nonazole CYP51 inhibitor
cures Chagas0 disease in a mouse model of acute infection. Antimicrobial Agents and Chemotherapy
54: 2480–2488. doi: 10.1128/AAC.00281-10 PMID: 20385875
45. Lepesheva GI, Waterman MR (2011) Structural basis for conservation in the CYP51 family. Biochimica
Et Biophysica Acta 1814: 88–93. doi: 10.1016/j.bbapap.2010.06.006 PMID: 20547249
46. Cherkesova TS, Hargrove TY, Vanrell MC, Ges I, Usanov SA, et al. (2014) Sequence variation in
CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition. Febs Letters 588:
3878–3885. doi: 10.1016/j.febslet.2014.08.030 PMID: 25217832
47. Kulkarni MM, Reddy N, Gude T, McGwire BS (2013) Voriconazole suppresses the growth of Leishman-
ia species in vitro. Parasitology Research 112: 2095–2099. doi: 10.1007/s00436-013-3274-x PMID:
23392902
48. Paniz Mondolfi AE, Stavropoulos C, Gelanew T, Loucas E, Perez Alvarez AM, et al. (2011) Successful
treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole.
Antimicrobial Agents and Chemotherapy 55: 1774–1776. doi: 10.1128/AAC.01498-10 PMID:
21282455
49. Rangel H, Dagger F, Hernandez A, Liendo A, Urbina JA (1996) Naturally azole-resistant Leishmania
braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study
with azole-susceptible Leishmania mexicana promastigotes. Antimicrobial Agents and Chemotherapy
40: 2785–2791. PMID: 9124841
Essentiality of Leishmania donovani CYP51
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588 March 13, 2015 16 / 17
50. Cotrim PC, Garrity LK, Beverley SM (1999) Isolation of genes mediating resistance to inhibitors of nu-
cleoside and ergosterol metabolism in Leishmania by overexpression/selection. J Biol Chem 274:
37723–37730. PMID: 10608831
51. Lorente SO, Gomez R, Jimenez C, Cammerer S, Yardley V, et al. (2005) Biphenylquinuclidines as in-
hibitors of squalene synthase and growth of parasitic protozoa. Bioorganic & Medicinal Chemistry 13:
3519–3529.
52. Lorente SO, Rodrigues JCF, Jimenez CJ, Joyce-Menekse M, Rodrigues C, et al. (2004) Novel azaster-
ols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrobial Agents and
Chemotherapy 48: 2937–2950. PMID: 15273104
53. Dinesh N, Pallerla DS, Kaur PK, Kishore Babu N, Singh S (2014) Exploring Leishmania donovani 3-hy-
droxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, bio-
physical and inhibition studies. Microbial Pathogenesis 66: 14–23. doi: 10.1016/j.micpath.2013.11.001
PMID: 24239940
54. Friesen JA, Rodwell VW (2004) The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases.
Genome biology 5: 248. PMID: 15535874
55. Verma S, Mehta A, Shaha C (2011) CYP5122A1, a novel cytochrome P450 is essential for survival of
Leishmania donovani. Plos One 6: e25273. doi: 10.1371/journal.pone.0025273 PMID: 21966477
56. Kamhawi S, Modi GB, Pimenta PFP, Rowton E, Sacks DL (2000) The vectorial competence of Phlebo-
tomus sergenti is specific for Leishmania tropica and is controlled by species-specific, lipophosphogly-
can-mediated midgut attachment. Parasitology 121: 25–33. PMID: 11085222
57. Tzinia AK, Soteriadou KP (1991) Substrate-dependent pH optima of gp63 purified from seven strains of
Leishmania. Molecular and Biochemical Parasitology 47: 83–89. PMID: 1857388
58. Molina I, Gomez i Prat J, Salvador F, Trevino B, Sulleiro E, et al. (2014) Randomized trial of posacona-
zole and benznidazole for chronic Chagas0 disease. The New England journal of medicine 370:
1899–1908. doi: 10.1056/NEJMoa1313122 PMID: 24827034
Essentiality of Leishmania donovani CYP51
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588 March 13, 2015 17 / 17
